New Zealand markets open in 6 hours 36 minutes

argenx SE (ARGX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
381.81+3.85 (+1.02%)
As of 11:24AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close377.96
Open382.90
Bid275.07 x 200
Ask490.96 x 200
Day's range379.39 - 382.90
52-week range327.73 - 550.76
Volume70,822
Avg. volume258,624
Market cap22.949B
Beta (5Y monthly)0.34
PE ratio (TTM)N/A
EPS (TTM)-5.67
Earnings date25 Jul 2024 - 29 Jul 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est478.62
  • GlobeNewswire

    argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcoming R&D Day on July 16, 2024

    R&D Day presentations to include recent Phase 2 datasets in Sjogren’s disease (efgartigimod) and multifocal motor neuropathy (empasiprubart) that support advancement to Phase 3 development Next wave of innovative pipeline candidates to be introduced highlighting long-term commitment to transform autoimmunity Decision to not advance development of efgartigimod in PC-POTS based on Phase 2 ALPHA data June 17, 2024, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a glob

  • GlobeNewswire

    argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference

    June 4, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024 at 2:40 PM ET in Miami, FL. A live webcast of the fireside chat may be accessed on the Investors section of the argenx website at argenx.com/inv

  • Investor's Business Daily

    After Biohaven Kerfuffle, Immunovant Dives On A Surprise Delay

    Immunovant stock slumped Thursday — reversing a day-earlier jump — after pivoting its focus to what one analyst called "a backup compound."